Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,684 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Peptides-Coated Oncolytic Vaccines for Cancer Personalized Medicine.
Feola S, Russo S, Martins B, Lopes A, Vandermeulen G, Fluhler V, De Giorgi C, Fusciello M, Pesonen S, Ylösmäki E, Antignani G, Chiaro J, Hamdan F, Feodoroff M, Grönholm M, Cerullo V. Feola S, et al. Among authors: russo s. Front Immunol. 2022 Apr 14;13:826164. doi: 10.3389/fimmu.2022.826164. eCollection 2022. Front Immunol. 2022. PMID: 35493448 Free PMC article.
Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids.
Hamdan F, Ylösmäki E, Chiaro J, Giannoula Y, Long M, Fusciello M, Feola S, Martins B, Feodoroff M, Antignani G, Russo S, Kari O, Lee M, Järvinen P, Nisen H, Kreutzman A, Leusen J, Mustjoki S, McWilliams TG, Grönholm M, Cerullo V. Hamdan F, et al. Among authors: russo s. J Immunother Cancer. 2021 Aug;9(8):e003000. doi: 10.1136/jitc-2021-003000. J Immunother Cancer. 2021. PMID: 34362830 Free PMC article.
PeptiCHIP: A Microfluidic Platform for Tumor Antigen Landscape Identification.
Feola S, Haapala M, Peltonen K, Capasso C, Martins B, Antignani G, Federico A, Pietiäinen V, Chiaro J, Feodoroff M, Russo S, Rannikko A, Fusciello M, Koskela S, Partanen J, Hamdan F, Tähkä SM, Ylösmäki E, Greco D, Grönholm M, Kekarainen T, Eshaghi M, Gurvich OL, Ylä-Herttuala S, M Branca RM, Lehtiö J, Sikanen TM, Cerullo V. Feola S, et al. Among authors: russo s. ACS Nano. 2021 Oct 26;15(10):15992-16010. doi: 10.1021/acsnano.1c04371. Epub 2021 Oct 4. ACS Nano. 2021. PMID: 34605646 Free PMC article.
Development of mesothelioma-specific oncolytic immunotherapy enabled by immunopeptidomics of murine and human mesothelioma tumors.
Chiaro J, Antignani G, Feola S, Feodoroff M, Martins B, Cojoc H, Russo S, Fusciello M, Hamdan F, Ferrari V, Ciampi D, Ilonen I, Räsänen J, Mäyränpää M, Partanen J, Koskela S, Honkanen J, Halonen J, Kuryk L, Rescigno M, Grönholm M, Branca RM, Lehtiö J, Cerullo V. Chiaro J, et al. Among authors: russo s. Nat Commun. 2023 Nov 3;14(1):7056. doi: 10.1038/s41467-023-42668-7. Nat Commun. 2023. PMID: 37923723 Free PMC article.
PeptiVAX: A new adaptable peptides-delivery platform for development of CTL-based, SARS-CoV-2 vaccines.
Feola S, Chiaro J, Fusciello M, Russo S, Kleino I, Ylösmäki L, Kekäläinen E, Hästbacka J, Pekkarinen PT, Ylösmäki E, Capone S, Folgori A, Raggioli A, Boni C, Tiezzi C, Vecchi A, Gelzo M, Kared H, Nardin A, Fehlings M, Barban V, Ahokas P, Viitala T, Castaldo G, Pastore L, Porter P, Pesonen S, Cerullo V. Feola S, et al. Among authors: russo s. Int J Biol Macromol. 2024 Mar;262(Pt 1):129926. doi: 10.1016/j.ijbiomac.2024.129926. Epub 2024 Feb 6. Int J Biol Macromol. 2024. PMID: 38331062
Novel peptide-based oncolytic vaccine for enhancement of adaptive antitumor immune response via co-engagement of innate Fcγ and Fcα receptors.
Feola S, Hamdan F, Russo S, Chiaro J, Fusciello M, Feodoroff M, Antignani G, D'Alessio F, Mölsä R, Stigzelius V, Bottega P, Pesonen S, Leusen J, Grönholm M, Cerullo V. Feola S, et al. Among authors: russo s. J Immunother Cancer. 2024 Mar 8;12(3):e008342. doi: 10.1136/jitc-2023-008342. J Immunother Cancer. 2024. PMID: 38458776 Free PMC article.
1,684 results